Pure Global AI
NCT06251843Not yet recruiting

Support Strategies for Parents During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder

Co-designing Support Strategies for Parents to Encourage Early Engagement With Health Services During the First Year Following Their Child's Diagnosis of Sickle Cell Disorder
King's College LondonClinicalTrials.gov
Study focus
Disease/Condition
Sickle Cell Disease
Study type
Observational
Sponsor & location
Primary sponsor
King's College London
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Feb 28, 2025
Enrollment
30 participants
Primary outcome

Support strategies for families with a child with SCD

Summary

Background: Sickle cell disorder (SCD), the commonest genetic (faulty gene inherited from
 both parents) condition in the UK, affects mainly underserved groups. Babies with SCD must
 start treatments soon after birth to prevent them becoming unwell. Stigma, fear and
 inequalities can make it difficult for parents to accept their child's diagnosis and access
 appropriate treatment and support.
 
 Aim: Develop strategies to improve support for parents during their child's first year of
 life following a SCD diagnosis to encourage early engagement with health services.
 
 Method: Comprises two stages: (i) Determine why parents choose to engage with support or not
 (ii) Use this information to co-design strategies to ensure greater accessibility of support
 for parents during their child's first year of life.
 
 Patient and Public Involvement: We are working with Sickle Cell Society and parents of
 children with SCD. Dissemination: Findings will be shared with support groups, charities,
 health professionals and academics.

ICD-10 classifications
Sickle-cell disordersOther sickle-cell disordersSickle-cell traitSickle-cell anaemia with crisisSickle-cell anaemia without crisis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06251843
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06251843 through Pure Global AI's free database. This phase not specified trial is sponsored by King's College London and is currently Not yet recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.